Teneligliptin in management of type 2 diabetes mellitus

Abstract

Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for the management of type 2 diabetes mellitus (T2DM) in adults along with diet and exercise. Teneligliptin has been recently available in Japan (Teneria®), Argentina (Teneglucon®), and India (Tenepure; Teneza) at relatively affordable price. This is a positive step toward the management of T2DM in developing countries, where the cost of medicine is out-of-pocket expenditure and is a limiting factor for health care. This review evaluates the efficacy and safety of teneligliptin in the management of T2DM. Teneligliptin has been systematically evaluated in T2DM as monotherapy with diet and exercise and in combination with metformin, glimepiride, pioglitazone, and insulin in short-term (12 weeks) and long-term (52 weeks) studies. These studies have reported a reduction in HbA1c of 0.8%–0.9% within 12 weeks of therapy. Two 52-week studies reported sustained improvement in glycemic control with teneligliptin. Teneligliptin has been found to be well tolerated, and the safety profile is similar to other dipeptidyl peptidase 4 inhibitors. Hypoglycemia and constipation are the main adverse events. Teneligliptin can be administered safely to patients with mild, moderate, or severe renal impairment or end-stage renal disease without dose adjustment. Similarly, it can be used in patients with mild-to-moderate hepatic impairment. Teneligliptin is effective and well tolerated and may have an important role in the management of T2DM.

Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

“…The incidences of AEs were not significantly different between the patients treated with teneligliptin and placebo. Although hypoglycemia was the main adverse event for T2DM patients (Sharma et al, 2016 ), teneligliptin led to a low risk of hypoglycemia. In addition, the cardiovascular effects of DPP-4 inhibitors remain controversial, while one DPP-4 inhibitor (saxagliptin) increased the risk of hospitalization for heart failure in the overall population; another(alogliptin) showed inconsistent effects on heart failure hospitalization across subgroups of patients, and a third(sitagliptin) had no effect on heart failure (Secrest et al, 2017 ).…”

“…In adults, teneligliptin is primarily metabolized by cytochrome P450 (CYP) 3A4 and flavin monooxygenases (FMO) (Patel et al, 2016 ). Approximately 34% of each administered dose of teneligliptin is excreted unchanged via the renal route, while 66% is metabolized and eliminated via the hepatic and renal routes (Sharma et al, 2016 ). Teneligliptin is usually orally administered at 20 mg once daily and increased to 40 mg once daily if the dosage is insufficient (Kishimoto, 2013 ).…”

Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies

“…Therapeutic options are often reduced in certain patient populations such as the elderly patients and those with impaired renal function. Teneligliptin can be administered to patients with renal dysfunction, including patients on dialysis, without the need for dose adjustment [ 30 , 31 ]. Our results may provide valuable information for diabetes therapy in patients, including those with limited therapeutic options.…”

Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes

“…[ 1 ] Globally, there are 415 million people with diabetes and the death toll of diabetes hit 5 million in 2015; moreover, the diabetes population is expected to rise to 642 million by 2040. [ 2 ] DM was divided into type 1and type 2 diabetes, and about 90% of DM patients are diagnosed with type 2 DM (T2DM). Good glycemic control plays an vital role in regulating blood glucose balance and reducing the occurrence of microvascular complications, including nephropathy, neuropathy, and retinopathy.…”